What is VYXEOS?
VYXEOS (vix-e-ose) is an intravenous (IV) chemotherapy used for the treatment of adults and pediatric patients 1 year and older with certain types of newly-diagnosed secondary acute myeloid leukemia (sAML): therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC).
You can learn more about VYXEOS by watching this video.
How is VYXEOS different?
VYXEOS is an advancement in chemotherapy used for the treatment of adults and pediatric patients 1 year and older with certain types of newly-diagnosed sAML: t-AML or AML-MRC. For these types of AML, VYXEOS is the only chemotherapy that combines 2 currently used, effective chemotherapies into tiny, bubble-like carriers called liposomes, which carry the drugs to the bone marrow. The liposomes are taken up by the blasts to a greater extent than by normal cells. Once inside, the liposomes release the drugs to help kill the blasts.a This type of technology, combining 2 drugs in this way, is the first of its kind in sAML treatment.
Chemotherapy solutions can be various colors. The VYXEOS solution is purple.
Chemotherapy may help patients get to remission and the opportunity to receive a stem cell transplant, if appropriate. Stem cell transplant may be used to replace blood-forming cells in the bone marrow that have been destroyed by treatment with chemotherapy or radiation. With a stem cell transplant, a person receives new cells from a donor’s blood or bone marrow that grow into healthy blood cells to replace the ones that were lost.
- Results based on early studies in animals.